이수앱지스

086890KOSDAQ의료용품 및 기타 의약 관련제품 제조업

51.5 / 100

Reference Date: 2026-07-24

Financial Score17.0 / 40

News Sentiment12.5 / 25

Momentum12.0 / 20

Disclosure10.0 / 15

AI Analysis: Revenue metrics are weak, ROE is below the industry average. Rose 9.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Isu Appgis primarily operates in the pharmaceutical sector, focusing on key products such as Absorcin (for Gaucher disease), Fabrazyme (for Fabry disease), and Clotyplast (an antibody therapy for cardiovascular conditions). In 2024, sales reached 60.3 billion won, a 11% increase from the previous year, with product sales accounting for 86.3% of total revenue. Product prices have remained stable over the past three years.

Number of Employees

190people

Average Salary

59.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.184.0Point

PBR

1.27Industry Average 1.092.5Point

Higher than industry avg (caution)

ROE

-9.92Industry Average -4.893.5Point

2.0x industry avg (excellent)

Debt Ratio

6.96Industry Average 6.862.0Point

Higher than industry avg (caution)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲2.5% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲78.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 3.9% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (15%, downtrend)

Current 3,560Won52-week high 6,24052-week low 3,060

1-month return5.0Point

1m +9.54% (rising)

Volume trend6.0Point

Volume surge

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral[기재정정]주식등의대량보유상황보고서(일반)2026-07-23
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-22
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-22
Neutral주식등의대량보유상황보고서(일반)2026-07-22